SanamLoghaviMD

Hematopathology, Molecular Genetics, Anatomic Pathology, Clinical Pathology

Assistant professor

Dr. Loghavi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 2013 - 2014
University of Texas M.D. Anderson Cancer CenterSelective Pathology, 2012 - 2013
Cedars-Sinai Medical CenterResidency, Pathology-Anatomic and Clinical, 2008 - 2012
Azad UniversityClass of 2004

PubMed

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12
The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome.
Yiannis Petros Dimopoulos, Wei Wang, Sa A Wang, Sanam Loghavi, Courtney D DiNardo
American Journal of Hematology. 2024-12-01
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.
Fadi G Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park
JCO Oncology Practice. 2024-12-01

Journal Articles

Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)
Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood

Abstracts/Posters

Higher Stability of Mutant IDH1/2 mRNA As Compared to Wild-Type mRNA in Patients with Acute Myeloid Leukemia
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics ...
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Expression Profiling of mRNA By Next Generation Sequencing and the Development of Algorithm for Predicting Response in Acute Myeloid Leukemia
Sanam Loghavi, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Five-Day Versus Ten-Day Schedules of Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase II Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018